CARA THERAPEUTICS INC's ticker is CARA and the CUSIP is 140755109. A total of 164 filers reported holding CARA THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.21 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,977,627 | -40.4% | 1,772,397 | +0.5% | 0.07% | -37.2% |
| Q2 2023 | $4,992,689 | -41.3% | 1,764,201 | +1.8% | 0.11% | -48.2% |
| Q1 2023 | $8,505,961 | -54.0% | 1,732,375 | +0.6% | 0.22% | -54.0% |
| Q4 2022 | $18,499,016 | +16.2% | 1,722,441 | +1.3% | 0.47% | +7.2% |
| Q3 2022 | $15,914,000 | +2.6% | 1,700,230 | +0.1% | 0.44% | +6.0% |
| Q2 2022 | $15,510,000 | -24.7% | 1,698,822 | +0.3% | 0.42% | -6.7% |
| Q1 2022 | $20,586,000 | +2.0% | 1,694,350 | +2.3% | 0.45% | +10.1% |
| Q4 2021 | $20,181,000 | -21.7% | 1,656,861 | -0.7% | 0.41% | -20.5% |
| Q3 2021 | $25,787,000 | +167.8% | 1,669,089 | +147.3% | 0.51% | +177.7% |
| Q2 2021 | $9,630,000 | -25.3% | 674,846 | +13.7% | 0.18% | -29.5% |
| Q1 2021 | $12,885,000 | +23.4% | 593,483 | -14.0% | 0.26% | +29.9% |
| Q4 2020 | $10,438,000 | +11.9% | 689,899 | -5.9% | 0.20% | -7.8% |
| Q3 2020 | $9,332,000 | -25.5% | 733,347 | +0.1% | 0.22% | -28.1% |
| Q2 2020 | $12,523,000 | +25.3% | 732,347 | -3.2% | 0.30% | +32.9% |
| Q1 2020 | $9,994,000 | -26.1% | 756,538 | -9.8% | 0.23% | +2.2% |
| Q4 2019 | $13,515,000 | -11.9% | 838,914 | +0.0% | 0.22% | -21.5% |
| Q3 2019 | $15,334,000 | -14.9% | 838,861 | +0.1% | 0.28% | -15.2% |
| Q2 2019 | $18,023,000 | +7.7% | 838,278 | -1.7% | 0.34% | +14.3% |
| Q1 2019 | $16,734,000 | +51.9% | 852,892 | +0.7% | 0.29% | +29.1% |
| Q4 2018 | $11,016,000 | -45.9% | 847,383 | -0.3% | 0.23% | -33.4% |
| Q3 2018 | $20,350,000 | +23.8% | 849,682 | -1.0% | 0.34% | +12.5% |
| Q2 2018 | $16,436,000 | +54.5% | 858,287 | -0.1% | 0.30% | +45.0% |
| Q1 2018 | $10,641,000 | +0.9% | 859,565 | -0.2% | 0.21% | +0.5% |
| Q4 2017 | $10,541,000 | -9.3% | 861,219 | +1.4% | 0.21% | -14.8% |
| Q3 2017 | $11,625,000 | -13.8% | 849,150 | -3.1% | 0.24% | -13.2% |
| Q2 2017 | $13,483,000 | -16.4% | 876,075 | -0.1% | 0.28% | -21.7% |
| Q1 2017 | $16,120,000 | +95.4% | 876,550 | -1.3% | 0.36% | +91.0% |
| Q4 2016 | $8,251,000 | – | 888,125 | – | 0.19% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 2,204,449 | $10,824 | 1.35% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 1,233,000 | $6,054,030 | 1.14% |
| Chescapmanager LLC | 1,160,392 | $5,698 | 0.90% |
| DISCIPLINED GROWTH INVESTORS INC /MN | 1,732,375 | $8,505,961 | 0.22% |
| XTX Topco Ltd | 107,610 | $528,365 | 0.11% |
| IQ EQ FUND MANAGEMENT (IRELAND) Ltd | 84,530 | $415,042 | 0.08% |
| PINNACLE ASSOCIATES LTD | 679,413 | $3,335,918 | 0.07% |
| PDT Partners, LLC | 102,010 | $500,869 | 0.07% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,995,370 | $9,797,267 | 0.05% |
| AXQ CAPITAL, LP | 27,760 | $136,302 | 0.05% |